



DOCKET NO.: BMS 2601/PH 7384DIV

PATENT

PH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Shuang Liu

Confirmation No.: Not Yet Assigned

Application No.: 10/803,724

Group Art Unit: Not Yet Assigned

Filing Date: March 18, 2004

Examiner: Not Yet Assigned

**For: N-SUBSTITUTED 3-HYDROXY-4-PYRIDINONES AND
PHARMACEUTICALS CONTAINING THEREOF**

DATE OF DEPOSIT:

August 20, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☒ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

EXCEPT THAT:


- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
 - ☒ Copies of references **1-65, 70-83 and 86-104** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **10/358,835, filed February 5, 2003.**

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

The PTO did not receive the following
listed item(s) Copies of References 84-85

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ English language abstracts have been provided for references **105 and 106** which are not in the English.

Date: August 20, 2004


Wendy A. Choi
Registration No. 36,697

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Abeyasinghe, R.D., et al., "The environment of the lipoxygenase iron binding site explored with novel hydroxypyridine iron chelators," <i>J. of Biological Chem.</i> , 1996 , 271(44), 7965-7972	
	2	Ahmed, S.I., et al., "The structures of bis-maltolato-zinc(II) and of bis-3-hydroxy-1,2-dimethyl-4-pyridinonato-zinc(II) and-lead(II)," <i>Polyhedron</i> , 2000 , 19, 129-135	
	3	Barret, M.C., et al., "Synthesis and structural characterization of Tin(II) and Zinc(II) derivatives of cyclic α -hydroxyketones, including the structures of Sn(mltol) ₂ , Sn(tropolone) ₂ , Zn(tropolone) ₂ , and Zn(hinokitiol) ₂ ," <i>Inorg. Chem.</i> , 2001 , 40, 4384-4388	
	4	Bebbington, D., et al., "3,5-disubstituted-4-hydroxyphenyls linked to 3-hydroxy-2-methyl-4(1H)-pyridinone: potent inhibitors of lipid peroxidation and cell toxicity," <i>J. Med. Chem.</i> , 2000 , 43, 2779-2782	
	5	Bickerdike, M.J., et al., "Enhanced acetylcholine release in striatum after chronic amphetamine is NMDA-dependent," <i>NeuroReport</i> , 1999 , 10, 77-80	
	6	Bosquet, J.-C., et al., "Gd-DOTA: characterization of a new paramagnetic complex," <i>Radiology</i> , 1988 , 166, 693-698	
	7	Branen, A.L., et al., "Use of antioxidants in self-preserving cosmetic and drug formulations," <i>Cosmet. Sci. Technol. Ser.</i> , 1997 , 16, 159-179	
	8	Brewer, G.J., "Cooper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's Disease," <i>Exp. Biol. Med.</i> , 2001 , 226(7), 665-673	
	9	CAPLUS Accession No. 1995:887972 (English abstract of Japanese Patent)	
	10	Caravan, P., et al., "Gadolinium(III) chelates as MRI contrast agents: structure, dynamics and applications," <i>Chem. Rev.</i> , 1999 , 99, 2293-2352	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	11	Caravan, P., et al., "Reaction chemistry of BMOV, Bis(maltolato)oxovanadium(IV)—apotent insulin mimetic agent," <i>J. Am. Chem. Soc.</i> , 1995 , <i>117</i> , 12759-12770
	12	Clarke, E.T., et al., "Stabilities of 1,2-dimethyl-3-hydroxy-4-pyridinone chelates of divalent and trivalent metal ions," <i>Inorganica Chimica Acta</i> , 1992 , <i>191</i> , 57-63
	13	Dobbin, P.S., et al., "Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1 <i>H</i>)-pyridinones: orally active iron chelators with clinical potential," <i>J. Med. Chem.</i> , 1993 , <i>36</i> , 2448-2458
	14	Dutt, N.K., et al., "Chemistry of lanthanons—XL1. isolation and characterization of tris chelates of lanthanides with maltol, kojic acid and chloro-kojic acid," <i>J. Inorg. Nucl. Chem.</i> , 1975 , <i>37</i> , 1801-1802
	15	Edwards, D.S., et al., "Characterization of Tris(N-substituted-2-methyl-3-hydroxy-4-pyridinonato)technetium(IV)cations," <i>Inorg. Chem.</i> , 1994 , <i>33</i> , 5607-5609
	16	Edwards, D.S., et al., "Potential ^{99m} Tc radiopharmaceuticals for renal imaging: tris(N-substituted-3-hydroxy-2-methyl-4-pyridinonato)technetium(IV)cations," <i>Nucl. Med. Biol.</i> , 1993 , <i>20</i> (7), 857-863
	17	El-Jammal, A., et al., "Cooper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies," <i>J. Med. Chem.</i> , 1994 , <i>37</i> , 461-466
	18	Ellis, B.L., et al., "6-alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labeling with indium," <i>Eur. J. Nucl. Med.</i> , 1999 , <i>26</i> , 1400-1406
	19	Ellis, B.L., et al., "Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling," <i>J. med. Chem.</i> , 1996 , <i>39</i> , 3659-3670
	20	Faller, B., et al., "Improving the oral bioavailability of the iron chelator HBED by breaking the symmetry of the intramolecular H-bond network," <i>J. Med. Chem.</i> , 2000 , <i>43</i> , 1467-1475
EXAMINER		DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	21	Fernandez, J.A., et al., "Essential viral and cellular zinc and iron containing metalloproteins as targets for novel antiviral and anticancer agents: implications for prevention and therapy of viral diseases and cancer," <i>Anticancer Res.</i> , 2001 , <i>21</i> , 931-958	
	22	Ferrali, M., et al., "3-hydroxy-(4H)-benzopyran-4-ones as potential iron chelating agents in vivo," <i>Bioorganic & Medicinal Chem.</i> , 2001 , <i>9</i> , 3041-3047	
	23	Foda, H.D., et al., "Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis," <i>DDT</i> , 2001 , <i>9</i> , 478-482	
	24	Gutteridge, J.M.C., et al., "Iron toxicity and oxygen radicals," <i>Ballièr's Clin. Haematology</i> , 1989 , <i>2(2)</i> , 195-256	
	25	Gwyn, K., et al., "Breast cancer during pregnancy," <i>Oncology</i> , 2001 , <i>15(1)</i> , 39-46	
	26	Hashimoto, M., et al., "Oxidative stress induces amyloid-like aggregate formation of NACP/ α -synuclein <i>in vitro</i> ," <i>NeuroReport</i> , 1999 , <i>10</i> , 717-721	
	27	Henrotin, Y., et al., "The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives," <i>Expert Opin. Ther. Patents</i> , 2002 <i>12(1)</i> , 29-43	
	28	Hidalgo, M., et al., "Development of matrix metalloproteinase inhibitors in cancer therapy," <i>J. of the National Cancer Institute</i> , 2001 , <i>93(3)</i> , 178-193	
	29	Hider, R.C., et al., "Design of orally active iron chelators," <i>Acta Haematol</i> , 1996 , <i>95</i> , 6-12	
	30	Hu, T.C.-C., et al., "Manganese-enhanced MRI of mouse heart during changes in inotropy," <i>Magnetic Resonance in Medicine</i> , 2001 , <i>46</i> , 884-890	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	31	Hunter, D.R., et al., "Comparison of Ca^{2+} , Sr^{2+} , and Mn^{2+} fluxes in mitochondria of the perfused rat heart," <i>Circ. Res.</i> , 1980 , 47, 721-727	
	32	John A., et al., "The role of matrix metalloproteinases in tumor angiogenesis of tumor metastasis," <i>Pathology Oncology Res.</i> , 2001 , 7(1), 14-23	
	33	Liu, Z.D., et al., "Design, synthesis and evaluation of <i>N</i> -basis substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotropic potential," <i>J. Pharm. Pharmacol.</i> , 2000 , 52, 263-272	
	34	Liu, Z.D., et al., "Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase," <i>Biochem. Pharmac.</i> , 2001 , 285-290	
	35	Liu, Z.D., et al., "Synthesis of 2-amido-3-hydroxypyridin-4(1 <i>H</i>)-ones: novel iron chelators with enhanced pFe^{3+} values," <i>bioorganic & Medicinal Chem.</i> , 2001 , 9, 563-573	
	36	Magerstädt, M., et al., "Gd(DOTA): an alternative to Gd(DTPA) as a $T_{1,2}$ relaxation agent for NMR imaging or spectroscopy," <i>Magnetic Resonance in Medicine</i> , 1986 , 3, 808-812	
	37	Martell, A.E., et al., "New chelating agents suitable for the treatment of iron overload," <i>Inorganica Chimica Acta</i> , 1999 , 291, 238-246	
	38	Matthews, A.J., et al., "Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1)," <i>J. of Surg. Res.</i> , 1997 , 73, 35-40	
	39	McCawley, L.J., et al., "Matrix metalloproteinases: multifunctional contributors to tumor progression," <i>Molecular Medicine Today</i> , 2000 , 6, 149-156	
	40	McNeill, J.H., et al., "Bis(maltolato)oxovanadium(IV) is a potent insulin mimic," <i>J. Med. Chem.</i> , 1992 , 35, 1489-1491	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	41	Melchoir, M., et al., "Vanadium complexes as insulin mimetic agents: coordination chemistry and in vivo studies of oxovanadium(IV) and dioxovanadate(V) complexes formed from naturally occurring chelating oxazolate, thiazolate, or picolinate units," <i>Inorg. Chem.</i> , 1999 , 38, 2288-2293
	42	Molenda, J.J., et al., "Enhancement of iron excretion via monoanionic 3-hydroxypyrid-4-ones," <i>J. Med. Chem.</i> , 1994 , 37, 93-98
	43	Narita, K., et al., "Mn and Mg influxes through Ca channels of motor nerve terminals are prevented by verapamil in frogs," <i>Brain Res.</i> , 1990 , 510, 289-295
	44	Naughton, D.P., et al., "EDTA bis-(ethyl phenylalaninate): a novel transition metal-ion chelating hydroxyl radical scavenger with a potential anti-inflammatory role," <i>Bioorganic & Medicinal Chem. Letts.</i> , 2001 , 11, 2573-2575
	45	Piyamongkol, S., et al., "Novel synthetic approach to 2-(1'-hydroxyalkyl)-and 2-amido-3-hydroxypyridin-4-ones," <i>Tetrahedron</i> , 2001 , 57, 3479-3486
	46	Porter, J.B., "A risk-benefit assessment of iron-chelation therapy," <i>Drug Safety</i> , 1997 , 17(6), 407-421
	47	Rai, B.L., et al., "Synthesis, physicochemical properties and biological evaluation of ester prodrugs of 3-hydroxypyridin-4-ones: design of orally active chelators with clinical potential," <i>Eur. J. Med. Chem.</i> , 1999 , 34, 475-485
	48	Rai, B.L., et al., "Synthesis, physicochemical properties, and evaluation of <i>N</i> -substituted-2-alkyl-3-hydroxy-4(1 <i>H</i>)-pyridinones," <i>J. Med. Chem.</i> , 1998 , 41, 3347-3359
	49	Rangel, M., "Pyridinone oxovanadium(IV) complexes: a new class of insulin mimetic compounds," <i>Transition Metal Chem.</i> , 2001 , 26, 219-223
	50	Remington's Pharmaceutical Sciences, 17 th Ed., <i>Mack Publishing Co.</i> , 1985 , page 1418
EXAMINER		DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	51	Runge, V.M., "Safety of approved MR contrast media for intravenous injection," <i>J. of Magnetic Resonance Imaging</i> , 2000 , <i>12</i> , 205-213	
	52	Runge, V.M., et al., "MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA," <i>Radiology</i> , 1988 , <i>166</i> , 835-838	
	53	Sakurai, H., et al., "Cysteine methyl ester-oxovanadium(IV) complex, preparation and characterization," <i>Inorganica Chimica Acta</i> , 1980 , <i>46</i> , L119-L120	
	54	Shibuya, I., et al., "Indications from Mn-quenching of fura-2 fluorescence in melanotrophs that dopamine and baclofen close Ca channels that are spontaneously open by not those opened by high $[K^+]_o$, and that Cd preferentially blocks the latter," <i>Cell Calcium</i> , 1993 , <i>14</i> , 33-44	
	55	Singh, S., et al., "Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones," <i>Drug Metabolism and Disposition</i> , 1992 , <i>20</i> (2), 256-261	
	56	Skiles, J.W., et al., "The design, structure and therapeutic application of matrix metalloproteinase inhibitors," <i>Curr. Med. Chem.</i> , 2001 , <i>8</i> , 425-474	
	57	Streater, M., et al., "Novel 3-hydroxy-2(1 <i>H</i>)-pyridinones. Synthesis, iron(III)-chelating properties, and biological activity," <i>J. Med. Chem.</i> , 1990 , <i>33</i> , 1749-1755	
	58	Thomas, et al., "Chemotherapeutic studies in the heterocyclic series. Reaction of kojic acid with hydrazine. Reaction of kojic acid ethers with hydrazine," <i>Helvetica Chimica Acta</i> , 1960 , <i>43</i> , 469-477	
	59	Thompson, K.H., et al., "Coordination chemistry of vanadium in metallopharmaceutical candidates compounds," <i>Coordination Chem. Rev.</i> , 2001 , <i>Vol.</i> 219-221, 1033-1053	
	60	Thompson, K.H., et al., "Design of vanadium compounds as insulin enhancing agents," <i>J. Chem. Soc., Dalton Trans.</i> , 2000 , 2885-2892	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
61	Whittaker, M., et al., "Design and therapeutic application of matrix metalloproteinase inhibitors," <i>Chem. Rev.</i> , 1999 , 99, 2735-2776	
62	Yuen, V.G., et al., "Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration," <i>Can. J. of Physiol. Pharmacol.</i> , 1995 , 73, 55-64	
63	Yuen, V.G., et al., "Glucose-lowering properties of vanadium compounds: comparison of coordination complexes with maltol or Kojic acid as ligands," <i>J. of Inorganic Biochem.</i> , 1997 , 68, 109-116	
64	Yuen, V.G., et al., "Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on <i>fa/fa</i> Zucker rats," <i>Can. J. Physiol. Pharmacol.</i> , 1996 , 74, 1001-1009	
65	Zhang, Z., et al., "Potential ⁶⁷ Ga radiopharmaceuticals for myocardial imaging: Tris(1-aryl-3-hydroxy-2-methyl-4-pyridinonato)gallium(III) complexes," <i>Nucl. Med. Biol.</i> , 1992 , 19(3), 327-335	
66	Dobbin, P.S., et al., "Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential," <i>J. Med. Chem.</i> , 1993 , 36, 2448-2458	
67	Edwards, D.S., et al., "Characterization of Tris(N-substituted-2-methyl-3-hydroxy-4-pyridinonato)technetium(IV) cations," <i>Inorg. Chem.</i> , 1994 , 33, 5607-5609	
68	Melchior, M., "Vanadium complexes as insulin mimetic agents: coordination chemistry and in vivo studies of oxovanadium(IV) and dioxovanadate(V) complexes formed from naturally occurring chelating oxazolate, thiazolate, or picolinate units," <i>Inorg. Chem.</i> , 1999 , 38, 2288-2293	
69	Rai, B.L., et al., "Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones," <i>J. Med. Chem.</i> , 1998 , 41, 3347-3359	
EXAMINER		DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. BMS-2601/ PH7384 DIV		Application No. 10/803,724	
				Applicant Shuang Liu			
				Filing Date March 18, 2004		Group Not Yet Assigned	
				Confirmation No. Not Yet Assigned			
U. S. PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	70	4,908,371	03/13/90	Moerker, et al.	514	318	
	71	5,087,440	02/11/92	Cacheris, et al.	424	9	
	72	5,155,215	10/13/92	Ranney	534	16	
	73	5,256,676	10/26/93	Hider, et al.	514	348	
	74	5,525,326	06/11/96	Unger	424	9.36	
	75	5,527,790	06/18/96	McNeill, et al.	514	186	
	76	5,688,815	11/18/97	Zbinden, et al.	514	348	
	77	5,716,598	02/10/98	Golman, et al.	424	9.36	
	78	5,866,563	02/02/99	McNeil, et al.	514	186	
	79	5,877,210	03/02/99	Schieven	514	492	
	80	5,980,863	11/09/99	Harnish, et al.	424	9.36	
	81	6,046,219	04/04/00	Hanauske-Abel, et al.	514	348	
	82	6,294,152 B1	09/25/01	Davies, et al.	424	9.361	
	83	6,323,340 B1	05/15/01	Zhang, et al.	514	492	
	84	2,136,807	11/15/38	Stoker	110	48	
	85	6,232,340	05/15/01	Zhang, et al.	514	492	
EXAMINER				DATE CONSIDERED			

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	86	WO 91/12822	09/05/91	PCT		
	87	WO 93/10822	06/10/93	PCT		
	88	WO 96/05867	02/29/96	PCT		
	89	WO 96/22021	07/25/96	PCT		
	90	WO 96/41639	12/27/96	PCT		
	91	WO 97/02842	01/30/97	PCT		
	92	WO 98/54138	12/03/98	PCT		
	93	WO 99/23075	05/14/99	PCT		
	94	WO 99/30562	06/24/99	PCT		
	95	WO 00/16736	03/30/00	PCT		
	96	WO 00/16782	03/30/00	PCT		
	97	WO 00/24730	05/04/00	PCT		
	98	WO 01/12168	02/22/01	PCT		
	99	0 335 745	10/04/89	EPO		
	100	1 006 108	06/07/00	EPO		
	101	1 006 112	06/07/00	EPO		
	102	2 269 589	02/16/94	UK		

EXAMINER

DATE CONSIDERED

<p>Form PTO-1449 Modified</p> <p>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</p> <p>U.S. Department of Commerce Patent and Trademark Office</p>	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER	DATE CONSIDERED
-----------------	------------------------